Inari Medical, Inc. (NASDAQ:NARI) CEO Sells $165,870.00 in Stock

Inari Medical, Inc. (NASDAQ:NARI) CEO Andrew Hykes sold 3,000 shares of the company’s stock in a transaction on Friday, December 20th. The stock was sold at an average price of $55.29, for a total transaction of $165,870.00. Following the transaction, the chief executive officer now owns 439,310 shares of the company’s stock, valued at approximately $24,289,449.90. The trade was a 0.68 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Andrew Hykes also recently made the following trade(s):

• On Tuesday, October 29th, Andrew Hykes sold 3,000 shares of Inari Medical stock. The stock was sold at an average price of $50.00, for a total transaction of $150,000.00.

Inari Medical Trading Up 1.9 %

Shares of NARI opened at $55.45 on Monday. The company has a 50-day moving average of $50.12 and a two-hundred day moving average of $48.14. The stock has a market cap of $3.25 billion, a P/E ratio of -41.07 and a beta of 0.97. Inari Medical, Inc. has a 12-month low of $36.73 and a 12-month high of $66.61.

Analysts Set New Price Targets

NARI has been the subject of a number of recent analyst reports. Leerink Partnrs upgraded shares of Inari Medical to a “hold” rating in a research report on Tuesday, September 3rd. Robert W. Baird raised their price target on Inari Medical from $66.00 to $67.00 and gave the company an “outperform” rating in a report on Tuesday, October 29th. Piper Sandler upped their price objective on Inari Medical from $50.00 to $52.00 and gave the stock a “neutral” rating in a report on Tuesday, October 29th. Stifel Nicolaus initiated coverage on Inari Medical in a report on Tuesday, September 17th. They issued a “hold” rating and a $50.00 target price for the company. Finally, Canaccord Genuity Group upped their price target on shares of Inari Medical from $71.00 to $74.00 and gave the stock a “buy” rating in a research note on Tuesday, October 29th. Six analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $61.80.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Franklin Resources Inc. increased its position in Inari Medical by 2.2% during the third quarter. Franklin Resources Inc. now owns 223,810 shares of the company’s stock worth $9,445,000 after buying an additional 4,899 shares in the last quarter. Barclays PLC boosted its stake in shares of Inari Medical by 9.7% during the third quarter. Barclays PLC now owns 288,079 shares of the company’s stock valued at $11,881,000 after acquiring an additional 25,365 shares during the last quarter. Y Intercept Hong Kong Ltd increased its position in Inari Medical by 316.7% during the 3rd quarter. Y Intercept Hong Kong Ltd now owns 44,318 shares of the company’s stock worth $1,828,000 after purchasing an additional 33,682 shares in the last quarter. Jane Street Group LLC raised its stake in Inari Medical by 32.4% in the 3rd quarter. Jane Street Group LLC now owns 95,223 shares of the company’s stock valued at $3,927,000 after purchasing an additional 23,286 shares during the last quarter. Finally, Point72 DIFC Ltd acquired a new position in Inari Medical in the 3rd quarter valued at about $9,008,000. 90.98% of the stock is currently owned by institutional investors and hedge funds.

Inari Medical Company Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.